BUPIVACAINE HEAVY INJECTION BP SOLUTION
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
11-12-2017
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
BUPIVACAINE HYDROCHLORIDE
Dostupné s:
AURO PHARMA INC
ATC kód:
N01BB01
INN (Mezinárodní Name):
BUPIVACAINE
Dávkování:
15MG
Léková forma:
SOLUTION
Složení:
BUPIVACAINE HYDROCHLORIDE 15MG
Podání:
INTRASPINAL
Jednotky v balení:
10X2ML AMPOULE
Druh předpisu:
Ethical
Terapeutické oblasti:
LOCAL ANESTHETICS
Přehled produktů:
Active ingredient group (AIG) number: 0108896002; AHFS:
Stav Autorizace:
APPROVED
Datum autorizace:
2017-12-11
Charakteristika produktu
_PAGE 1 OF 29 _
PRODUCT MONOGRAPH
BUPIVACAINE HEAVY INJECTION BP
Bupivacaine 0.75% in Glucose 7.5 mg/mL
_Local Anesthetic_
AURO PHARMA INC.
Date of Preparation:
3700 Steeles Avenue West, Suite # 402 December 11, 2017
Woodbridge, Ontario, L4L 8K8
CANADA
Submission Control No: 203187
_PAGE 2 OF 29 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
......................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
11
OVERDOSAGE
...............................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 16
STORAGE AND STABILITY
.........................................................................................
18
SPECIAL HANDLING INSTRUCTIONS
......................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 18
PART II: SCIENTIFIC INFORMATION
..............................................................................
19
PHARMACEUTICAL INFORMATION
.........................................................................
19
DETAILED PHARMACOLOGY
...............................................................
Přečtěte si celý dokument
